WO2015172872A1 - Verwendung von semifluorierten alkanen in transdermalen therapeutischen systemen - Google Patents
Verwendung von semifluorierten alkanen in transdermalen therapeutischen systemen Download PDFInfo
- Publication number
- WO2015172872A1 WO2015172872A1 PCT/EP2015/000937 EP2015000937W WO2015172872A1 WO 2015172872 A1 WO2015172872 A1 WO 2015172872A1 EP 2015000937 W EP2015000937 W EP 2015000937W WO 2015172872 A1 WO2015172872 A1 WO 2015172872A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tts
- sfas
- tts according
- active ingredient
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2948684A CA2948684C (en) | 2014-05-13 | 2015-05-07 | Use of semi-fluorinated alkanes in transdermal therapeutic systems |
KR1020167034687A KR102341106B1 (ko) | 2014-05-13 | 2015-05-07 | 경피 치료 시스템에서 세미-플루오르화된 알칸의 용도 |
CN201580025695.1A CN106456565A (zh) | 2014-05-13 | 2015-05-07 | 半氟化烷烃在透皮治疗系统中的用途 |
BR112016026354-5A BR112016026354B1 (pt) | 2014-05-13 | 2015-05-07 | Sistema terapêutico transdérmico e uso de alcanos semifluorados em tal sistema |
AU2015258459A AU2015258459B2 (en) | 2014-05-13 | 2015-05-07 | Use of semi-fluorinated alkanes in transdermal therapeutic systems |
ES15722654T ES2895481T3 (es) | 2014-05-13 | 2015-05-07 | Uso de alcanos semifluorados en sistemas terapéuticos transdérmicos |
JP2016567628A JP6637907B2 (ja) | 2014-05-13 | 2015-05-07 | 経皮治療システムにおける半フッ素化アルカン類の使用 |
US15/309,595 US20170182060A1 (en) | 2014-05-13 | 2015-05-07 | Use of semi-fluorinated alkanes in transdermal therapeutic systems |
EP15722654.9A EP3142648B1 (de) | 2014-05-13 | 2015-05-07 | Verwendung von semifluorierten alkanen in transdermalen therapeutischen systemen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14168081.9 | 2014-05-13 | ||
EP14168081.9A EP2944324A1 (de) | 2014-05-13 | 2014-05-13 | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015172872A1 true WO2015172872A1 (de) | 2015-11-19 |
Family
ID=50731930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2015/000937 WO2015172872A1 (de) | 2014-05-13 | 2015-05-07 | Verwendung von semifluorierten alkanen in transdermalen therapeutischen systemen |
Country Status (9)
Country | Link |
---|---|
US (1) | US20170182060A1 (de) |
EP (2) | EP2944324A1 (de) |
JP (1) | JP6637907B2 (de) |
KR (1) | KR102341106B1 (de) |
CN (1) | CN106456565A (de) |
AU (1) | AU2015258459B2 (de) |
CA (1) | CA2948684C (de) |
ES (1) | ES2895481T3 (de) |
WO (1) | WO2015172872A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101656121B1 (ko) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | 안압 증가를 치료하기 위한 약학 조성물 |
EP2444063A1 (de) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen |
PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
WO2013110621A1 (en) | 2012-01-23 | 2013-08-01 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
CN113679697A (zh) | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
JP6039152B2 (ja) | 2012-09-12 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ素化アルカン組成物 |
KR102272568B1 (ko) | 2013-07-23 | 2021-07-05 | 노바리크 게엠베하 | 안정화 항체 조성물 |
CN108349855B (zh) | 2015-09-30 | 2021-07-20 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
DE202016008738U1 (de) | 2015-09-30 | 2019-04-09 | Novaliq Gmbh | Semifluorierte Verbindungen und ihre Zusammensetzungen |
ES2763121T3 (es) | 2016-06-23 | 2020-05-27 | Novaliq Gmbh | Método de administración tópica |
CN116172987A (zh) | 2016-09-22 | 2023-05-30 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
CN110678207A (zh) | 2017-04-21 | 2020-01-10 | 诺瓦利克有限责任公司 | 碘组合物 |
US10717691B2 (en) | 2017-05-05 | 2020-07-21 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
CN111372566A (zh) | 2017-09-27 | 2020-07-03 | 诺瓦利克有限责任公司 | 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物 |
CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
SG11202007858VA (en) | 2018-03-02 | 2020-09-29 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
AU2019345929B2 (en) * | 2018-09-27 | 2022-02-03 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
KR20210068033A (ko) | 2018-09-27 | 2021-06-08 | 노바리크 게엠베하 | 지질 장벽 수복 |
SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992010231A1 (en) * | 1990-12-11 | 1992-06-25 | Theratech, Inc. | Subsaturated transdermal drug delivery device exhibiting enhanced drug flux |
US6262126B1 (en) * | 1995-09-29 | 2001-07-17 | Hasso Meinert | Semi-fluorinated alkanes and their use |
WO2012160180A2 (en) * | 2011-05-25 | 2012-11-29 | Novaliq Gmbh | Pharmaceutical composition for administration to nails |
WO2012160179A2 (en) * | 2011-05-25 | 2012-11-29 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3046346B2 (ja) * | 1990-03-12 | 2000-05-29 | 昭和電工株式会社 | 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤 |
DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
DE10042412B4 (de) | 2000-08-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung |
DE102005050431A1 (de) | 2005-10-21 | 2007-04-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe |
EP2332525A1 (de) * | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmazeutische Zusammensetzung mit Propofol |
US20130338122A1 (en) * | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
-
2014
- 2014-05-13 EP EP14168081.9A patent/EP2944324A1/de not_active Withdrawn
-
2015
- 2015-05-07 EP EP15722654.9A patent/EP3142648B1/de active Active
- 2015-05-07 CN CN201580025695.1A patent/CN106456565A/zh active Pending
- 2015-05-07 JP JP2016567628A patent/JP6637907B2/ja active Active
- 2015-05-07 CA CA2948684A patent/CA2948684C/en active Active
- 2015-05-07 KR KR1020167034687A patent/KR102341106B1/ko active IP Right Grant
- 2015-05-07 AU AU2015258459A patent/AU2015258459B2/en active Active
- 2015-05-07 US US15/309,595 patent/US20170182060A1/en active Pending
- 2015-05-07 ES ES15722654T patent/ES2895481T3/es active Active
- 2015-05-07 WO PCT/EP2015/000937 patent/WO2015172872A1/de active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992010231A1 (en) * | 1990-12-11 | 1992-06-25 | Theratech, Inc. | Subsaturated transdermal drug delivery device exhibiting enhanced drug flux |
US6262126B1 (en) * | 1995-09-29 | 2001-07-17 | Hasso Meinert | Semi-fluorinated alkanes and their use |
WO2012160180A2 (en) * | 2011-05-25 | 2012-11-29 | Novaliq Gmbh | Pharmaceutical composition for administration to nails |
WO2012160179A2 (en) * | 2011-05-25 | 2012-11-29 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
Also Published As
Publication number | Publication date |
---|---|
JP6637907B2 (ja) | 2020-01-29 |
CN106456565A (zh) | 2017-02-22 |
US20170182060A1 (en) | 2017-06-29 |
KR102341106B1 (ko) | 2021-12-20 |
EP2944324A1 (de) | 2015-11-18 |
EP3142648B1 (de) | 2021-09-29 |
EP3142648A1 (de) | 2017-03-22 |
ES2895481T3 (es) | 2022-02-21 |
AU2015258459B2 (en) | 2020-05-28 |
CA2948684A1 (en) | 2015-11-19 |
CA2948684C (en) | 2023-04-18 |
AU2015258459A1 (en) | 2016-12-22 |
KR20170005087A (ko) | 2017-01-11 |
JP2017515855A (ja) | 2017-06-15 |
BR112016026354A8 (pt) | 2018-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3142648B1 (de) | Verwendung von semifluorierten alkanen in transdermalen therapeutischen systemen | |
EP1937227B1 (de) | Transdermales therapeutisches system zur verabreichung lipophiler und/oder wenig hautpermeabler wirkstoffe | |
EP0813865B1 (de) | Wirkstoffpflaster | |
DE60021099T2 (de) | Transdermale, in form einer haftschicht ausgebildete zweifachmedikamenten-verabreichungsvorrichtung | |
JP7145363B2 (ja) | 局所皮膜形成スプレー | |
EP1827398B1 (de) | Transdermales therapeutisches system mit aktivierbarer übersättigung und kontrollierter permeationsförderung | |
DE112014002664T5 (de) | Transdermales Verabreichungssystem | |
WO2001001967A1 (de) | Mikroreservoirsystem auf basis von polysiloxanen und ambiphilen lösemitteln | |
US20130211353A1 (en) | Percutaneous absorption type formulation | |
EP1064939A2 (de) | Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemetischen Behandlung | |
EP1267846B1 (de) | Transdermales therapeutisches system zur abgabe von lerisetron | |
EP2178523A2 (de) | Transdermale therapeutische systeme, welche den wirkstoff anastrozol enthalten | |
US9254325B2 (en) | Percutaneously absorbed preparation | |
DE10025971B4 (de) | Transdermales therapeutisches System in Plasterform mit verminderter Tendenz zur Wirkstoffkristallisation und seine Verwendung | |
DE19932651A1 (de) | Transdermales therapeutisches System zur Anwendung von Tolterodin | |
AU2018101236A4 (en) | Transdermal delivery of lidocaine prilocaine mixture from cataplasm matrix | |
WO2021191136A1 (de) | Dmeh - enhancer | |
BR112016026354B1 (pt) | Sistema terapêutico transdérmico e uso de alcanos semifluorados em tal sistema |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15722654 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 15309595 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2948684 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016567628 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016026354 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20167034687 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015722654 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015722654 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015258459 Country of ref document: AU Date of ref document: 20150507 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016026354 Country of ref document: BR Kind code of ref document: A2 Effective date: 20161110 |